Comparative Pharmacology
Head-to-head clinical analysis: SUMYCIN versus TETREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUMYCIN versus TETREX.
SUMYCIN vs TETREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
None Documented
None Documented
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic